Shots:
- Genentech has reported 10yr. P-III (APHINITY) trial data assessing Perjeta + Herceptin & CT vs Herceptin + CT vs PBO as an adj. therapy in 4804 pts with operable HER2+ early-stage breast cancer
- After 10yrs, trial depicted improved OS, with 91.6% pts alive vs 89.8% on Herceptin + CT & PBO, with sustained invasive disease-free survival (1EP) benefit, though no benefit was seen in the node-negative subgroup
- Trial also showed reduced death risk by 17% overall & 21% in pts with lymph node-positive disease compared to those receiving Herceptin + CT & PBO; full data to be presented at ESMO Breast Cancer 2025
Ref: Businesswire| Image: Genentech| Press Release
Related News:- Repertoire Immune Medicines Collaborates with Genentech to Develop T cell-Targeted Therapies for an Autoimmune Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
